

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Offeror or the Company nor is it a solicitation of any vote or approval in any jurisdiction.



Grand Full Development Limited
(創隆發展有限公司)
*(Incorporated in Hong Kong with
limited liability)*

**Bloomage BioTechnology
Corporation Limited**
華熙生物科技股份有限公司
*(Incorporated in the Cayman Islands
with limited liability)*
(Stock Code: 00963)

**MONTHLY UPDATE ON
(1) PROPOSAL FOR THE PRIVATISATION OF
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED BY THE
OFFEROR BY WAY OF A SCHEME OF ARRANGEMENT
(UNDER SECTION 86 OF THE COMPANIES LAW)
AND
(2) PROPOSED WITHDRAWAL OF LISTING**

Financial Adviser to the Offeror



References are made to the joint announcement issued by Bloomage BioTechnology Corporation Limited (the “**Company**”) and Grand Full Development Limited (the “**Offeror**”) dated 19 June 2017 (the “**Joint Announcement**”) regarding the Proposal, the Scheme and the Option Offer and the announcement of the Company dated 10 July 2017 in relation to the extension of time for the despatch of the Scheme Document (the “**Extension Announcement**”). Unless otherwise defined herein, terms used herein shall have the same meanings as defined in the Joint Announcement.

The Company and the Offeror wish to update the Shareholders and potential investors of the Company on the progress relating to the Proposal, the Scheme and the Option Offer.

As set out in the Extension Announcement, as more time is required to accommodate the timetable of the Grand Court, an application for consent has been made to the Executive and the Executive has indicated that it is minded to grant consent for an extension to the time limit for despatching the Scheme Document to a date no later than 8 September 2017.

The Company and the Offeror are in the process of preparing the Scheme Document and have filed a petition, together with the draft Scheme Document, with the Grand Court for the convening hearing at which the Grand Court will consider and, if thought fit, grant an order for, among other things, despatching the Scheme Document and the associated notices of meeting and proxy forms, and convening the Court Meeting.

Further announcement(s) will be made by the Company and/or the Offeror to inform the Shareholders and potential investors of any material developments relating to the Proposal, the Scheme and the Option Offer and further announcement(s) will be made by the Company and/or the Offeror on a monthly basis to keep the Shareholders and potential investors updated on the Proposal, the Scheme and the Option Offer until the despatch of the Scheme Document.

Warnings:

Shareholders, Optionholders and potential investors should be aware that the implementation of the Proposal, the Scheme and/or the Option Offer is subject to the Conditions being fulfilled or waived, as applicable, and thus the Proposal, the Scheme and the Option Offer may or may not be implemented and the Scheme may or may not become effective.

Shareholders, Optionholders and potential investors should therefore exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their licensed securities dealers or registered institutions in securities, bank manager, solicitor or other professional advisers.

By Order of the Board of
Grand Full Development Limited
(創隆發展有限公司)
Zhao Yan
Director

By Order of the Board of
Bloomage BioTechnology Corporation Limited
華熙生物科技有限公司
Gong Anmin
Director

Hong Kong, 10 August 2017

As at the date of this joint announcement, the sole director of the Offeror is Ms. Zhao.

The sole director of the Offeror accepts full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Group) and confirms, having made all reasonable enquiries, that to the best of her knowledge, opinions expressed in this joint announcement (other than those expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.

As at the date of this joint announcement, the Directors are:

Executive Directors:
Ms. Zhao Yan
Mr. Jin Xuekun
Mr. Gong Anmin
Ms. Wang Aihua

Non-executive Director:
Mr. Yau Wai Yan

Independent non-executive Directors:
Ms. Zhan Lili
Mr. Li Junhong
Mr. Xue Zhaofeng

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Offeror) and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than those expressed by the Offeror) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.